Neutra Corp. (NTRR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 14.33 Thousand USD | -59.4% |
| 2023 | 35.3 Thousand USD | 13.3% |
| 2022 | 31.16 Thousand USD | 193.7% |
| 2021 | -33.25 Thousand USD | -620.05% |
| 2020 | 6395.00 USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 589.00 USD | -64.98% |
| 2024 Q1 | 2804.00 USD | -5.08% |
| 2024 Q4 | 2837.00 USD | 381.66% |
| 2024 FY | -33.9 Thousand USD | -196.03% |
| 2024 Q2 | 1682.00 USD | -40.01% |
| 2023 Q2 | 16.55 Thousand USD | 223.05% |
| 2023 FY | 35.3 Thousand USD | 13.3% |
| 2023 Q3 | 10.67 Thousand USD | -35.51% |
| 2023 Q1 | 5124.00 USD | -82.17% |
| 2023 Q4 | 2954.00 USD | -72.33% |
| 2022 Q1 | 1292.00 USD | 103.33% |
| 2022 Q4 | 28.74 Thousand USD | 1643.12% |
| 2022 Q2 | -524.00 USD | -140.56% |
| 2022 FY | 31.16 Thousand USD | 193.7% |
| 2022 Q3 | 1649.00 USD | 414.69% |
| 2021 Q3 | 726.00 USD | -74.22% |
| 2021 Q4 | -38.81 Thousand USD | -5446.01% |
| 2021 Q2 | 2816.00 USD | 39.89% |
| 2021 FY | -33.25 Thousand USD | -620.05% |
| 2021 Q1 | 2013.00 USD | -68.52% |
| 2020 FY | 6395.00 USD | 0.0% |
| 2020 Q4 | 6395.00 USD | 0.0% |
| 2020 Q1 | - USD | 100.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2019 Q1 | 2006.00 USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | -2006.00 USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | -100.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 687.741% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.878% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 104.487% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.988% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.056% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 129.704% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 111.537% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.904% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -362.121% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.854% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 78.19% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 141.977% |
| Mesoblast Limited | -35.16 Million USD | 100.041% |
| Marizyme, Inc. | 457.7 Thousand USD | 96.868% |
| Genus plc | 178.7 Million USD | 99.992% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.993% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 76.963% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 96.505% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 230.318% |
| ContraFect Corporation | -154 Thousand USD | 109.308% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 128.67% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 81.325% |
| IMV Inc. | -962.29 Thousand USD | 101.49% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 103.699% |
| MultiCell Technologies, Inc. | 49.32 USD | -28965.288% |
| ONE Bio Corp. | 20.12 Million USD | 99.929% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.964% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 70.685% |
| Q BioMed Inc. | -8988.00 USD | 259.49% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.949% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 192.94% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.968% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 101.256% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 79.521% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 389.479% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 89.797% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 114.7% |
| GB Sciences, Inc. | -624.00 USD | 2397.276% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 116.663% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 6991.827% |
| Enzolytics Inc. | 30.7 Thousand USD | 53.318% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 97.029% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.999% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 102.786% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 97.678% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.996% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 261.868% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 117.096% |
| Kadimastem Ltd | -630.13 Thousand USD | 102.275% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 98.549% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.851% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.907% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 221.124% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 91.881% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 91.881% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 98.944% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 149.431% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 96.815% |
| SYBLEU INC | 11.69 Thousand USD | -22.563% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 99.689% |
| Bioxytran, Inc. | -8285.00 USD | 273.024% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 103.843% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 117.482% |
| PureTech Health plc | -1.6 Million USD | 100.894% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 101.432% |
| IXICO plc | 3.27 Million USD | 99.562% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 102.066% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 100.8% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | 20.361% |